Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment

E Filippucci, A Farina, M Carotti, F Salaffi, W Grassi

**Objective:** To investigate the ability of high resolution grey scale sonography (GSS) and power Doppler sonography (PDS) to assess short term soft tissue changes induced by intra-articular steroid injection in the small joints of patients with chronic synovitis.

**Methods:** 20 patients with clinically active synovitis of a small joint unresponsive to systemic drug treatment underwent a sonographic guided intraartesional injection with triamcinolone acetonide. Clinical examinations were carried out by a trained rheumatologist. GSS and PDS examinations were performed independently by two examiners unaware of the results of the clinical examination. Joint cavity widening and power Doppler signal were evaluated and graded on a semiquantitative scale ranging from 1 to 4. Clinical and sonographic follow up examinations were carried out 2 weeks after the injection with triamcinolone acetonide.

**Results:** All intra-articular injections were successfully carried out and documented under sonographic guidance. In 19/20 patients, baseline sonographic examinations clearly detected morphological and perfusional signs of synovitis. At follow up examinations, clinical and sonographic scores had improved significantly.

**Conclusion:** GSS and PDS appear to be a useful adjunctive tool for assessing short term soft tissue changes induced by intra-articular injection treatment with triamcinolone acetonide in small joints of patients with chronic arthritis.

**Patients and Methods**

**Patients**

Table 1 presents the clinical and demographic features of the patients. All patients presented with clinically active synovitis of a small joint of the hand, wrist, or foot, unresponsive to systemic drug treatment. All patients underwent a sonographic guided intraartesional injection with triamcinolone acetonide. The dose of the steroid depended on the joint size, ranging from 10 mg for the small joints of the fingers to 30 mg for the radiocarpal joint. Except for local application of ice after the injection, no other changes in the pre-existing therapeutic regimen were made. No aspiration of synovial fluid was performed, because of the small size of the joints or the prevalence of synovial proliferation on effusion, or both.

**Clinical examination**

Clinical examination was carried out by a trained rheumatologist (FS). A visual analogue scale (VAS) for pain (ranging from 0 to 10) and a tenderness score (ranging from 0 to 3) were used as measures of disease activity.

**Sonographic examination**

Patients were examined with an AU5 Harmonic-Esaote Biomedica (Genoa, Italy), using a broadband linear probe with frequency ranging from 10 to 14 MHz. Power Doppler settings were standardised with a pulse repetition frequency of 1000 Hz and a colour-mode frequency of 7 MHz. Wall filters were set at the lowest value, while colour gain was increased to the highest value not generating power Doppler signals under the bony cortex. Each joint was explored for the highest level of expression of signs of synovitis, using a multiplanar examination according to the standard scanning protocol reported in the guidelines for musculoskeletal sonography. Particular attention was paid to avoiding any pressure on the skin in order to prevent synovial fluid dislocation or local blood flow reduction, or both. No standoff pad was used. The sonographic images showing the most representative features of synovitis were stored for the final assessment. Joint cavity widening and power Doppler signal were evaluated and graded on a semiquantitative scale ranging from 1 to 4: 1 = normal or minimal degree; 2 = mild degree; 3 = moderate degree; 4 = marked degree.

GSS and PDS examinations were performed independently by two experienced examiners (EF and AF) unaware of the results of clinical examination. The interobserver κ values for agreement between the two examiners for the assessment of GSS and PDS findings were respectively 0.868 (standard error (SE) = 0.158) and 0.953 (SE = 0.159) at baseline and 0.853 (SE = 0.174) and 0.901 (SE = 0.201) at follow up examinations. When the scores assigned by the two examiners did not match, they reached a consensus by re-examining the patient together as proposed by Walther et al.

**Follow up examinations**

Clinical and sonographic follow up examinations were carried out 2 weeks after the sonographic guided intraartesional injection with triamcinolone acetonide, with particular

**Abbreviations:** GSS, grey scale sonography; PDS, power Doppler sonography; VAS, visual analogue scale
Intra-articular steroid injection treatment

**RESULTS**

Sonographic guided intra-articular injections were successfully carried out in all patients (table 1).

At baseline clinical examinations, the median VAS value was 8 (95% confidence intervals (CI) 7 to 9), while the median tenderness value was 3 (95% CI 2 to 3). Baseline sonographic examinations detected clearly evident morphological (joint cavity widening) and perfusional (power Doppler signal) signs of synovitis in all patients except patient number 9. The median VSS score was 2 (95% CI 1 to 3), while the median PDS score was 3 (95% CI 2 to 4).

At follow-up clinical examinations, both VAS and tenderness scores had improved and a significant decrease of the VAS score (p < 0.01) and tenderness scores (p < 0.01) was found. A significant change was also detected for the sonographic findings between baseline and follow-up values of the GSS (p < 0.01) and PDS scores (p < 0.01).

In 14/20 (70%) patients reduction of both GSS and PDS scores was found. Figure 1 shows representative sonographic images of baseline and follow-up examinations of a patient with rheumatoid arthritis, documenting the decrease of the joint cavity widening and of the power Doppler signals. Figure 1 also shows a mild persistent increase of perfusion at the midcarpal joint as compared with the lack of any residual signs of active inflammation in the radiocarpal joint. A possible explanation of such a difference may be that in this patient there was no communication between radiocarpal and midcarpal joint, which is relatively common in patients with rheumatoid arthritis.

Four of 20 (20%) patients (patients numbers 1, 7, 17, and 19) achieved complete remission of pain and the disappearance of sonographic features of synovitis (fig 2).

In 3/20 (15%) patients (patients numbers 10, 11, and 13), both clinical and PDS scores were reduced, while no changes of the GSS score were detected at follow-up examinations. Three of 20 (15%) patients (patients numbers 5, 9, and 15) presented with no GSS and PDS score changes at follow-up examinations.

**DISCUSSION**

PDS has been shown to be a reliable method for assessing synovitis in patients with chronic arthritis. At present, however, there is little evidence to support the ability of PDS to demonstrate synovial perfusion changes induced by steroid treatment.

The only previous comparable study on PDS monitoring of intra-articular steroid injection treatment included seven patients with knee synovitis, five patients with rheumatoid arthritis, one patient with psoriatic arthritis, and one patient with calcium pyrophosphate dihydrate deposition disease. After a mean time of 7.4 days (range 4–15) clinical response was defined as “good” in six of seven patients.

The potential role of PDS in treatment monitoring was also explored by Stone et al in patients with rheumatoid hand synovitis. In that study, however, four patients received intravenous methylprednisolone (125 mg) for three consecutive days and the remaining eight patients received 20 mg oral prednisolone. The change in PDS signal in individual joints was described as “dramatic”.

**Table 1** Patients’ demographic characteristics, clinical diagnoses, anatomical sites injected, dose of triamcinolone acetonide, and baseline and follow-up clinical and sonographic scores

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Anatomical site</th>
<th>Diagnosis</th>
<th>Dose of triamcinolone acetonide (mg)</th>
<th>Baseline VAS (0–10)</th>
<th>Tenderness (0–3)</th>
<th>GSS* (1–4)</th>
<th>PDS* (1–4)</th>
<th>Follow up after 2 weeks VAS* (0–10)</th>
<th>Tenderness* (0–3)</th>
<th>GSS* (1–4)</th>
<th>PDS* (1–4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>20</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>32</td>
<td>M</td>
<td>Wrist</td>
<td>RA</td>
<td>20</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>81</td>
<td>M</td>
<td>Wrist</td>
<td>CPPD</td>
<td>30</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>82</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>30</td>
<td>9</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>64</td>
<td>F</td>
<td>MTP</td>
<td>RA</td>
<td>10</td>
<td>10</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>M</td>
<td>MTP</td>
<td>RA</td>
<td>10</td>
<td>10</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>30</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>20</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>F</td>
<td>MCP</td>
<td>PsA</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>55</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>30</td>
<td>10</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>82</td>
<td>F</td>
<td>MCP</td>
<td>PsA</td>
<td>10</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>68</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>30</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>63</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>30</td>
<td>8</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>30</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>37</td>
<td>F</td>
<td>PIP</td>
<td>PsA</td>
<td>10</td>
<td>10</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>70</td>
<td>M</td>
<td>Wrist</td>
<td>CPPD</td>
<td>30</td>
<td>8</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>70</td>
<td>F</td>
<td>Wrist</td>
<td>CPPD</td>
<td>30</td>
<td>8</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>30</td>
<td>M</td>
<td>DIP</td>
<td>PsA</td>
<td>10</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>31</td>
<td>M</td>
<td>DIP</td>
<td>PsA</td>
<td>10</td>
<td>6</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>30</td>
<td>M</td>
<td>Wrist</td>
<td>PsA</td>
<td>20</td>
<td>8</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>20</td>
<td>55</td>
<td>F</td>
<td>Wrist</td>
<td>RA</td>
<td>20</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Median</td>
<td>58</td>
<td>5F/SM</td>
<td></td>
<td></td>
<td></td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

*p < 0.01

GSS, grey scale ultrasonography; PDS, power Doppler ultrasonography; RA, rheumatoid arthritis; PsA, psoriatic arthritis; ReA, reactive arthritis; CPPD, calcium pyrophosphate deposition disease; MTP, metatarsophalangeal joint; MCP, metacarpophalangeal joint; PIP, proximal interphalangeal joint; DIP, distal interphalangeal joint.

Statistical analysis

All the recorded clinical and sonographic findings are qualitative variables. Significance testing was performed using the Wilcoxon signed rank test. A p value of < 0.05 was considered significant. The relationship between the clinical and sonographic (GSS and PDS) findings was analysed using Spearman’s rank correlation test. Statistical analysis was performed using MedCalc software (version 6.0) for Windows.
To the best of our knowledge, this is the first study that provides statistical evidence of the value of sonography in the detection of GSS and PDS changes induced by intra-articular steroid injection treatment in the small joints of patients with chronic arthritis.

Our data indicate that such changes can be clearly seen even after a very short term follow up. The reduction of PDS signals appears to be related to the improvement of symptoms of synovitis (pain and tenderness). Of interest, is that PDS can detect persistently active synovitis that may be underestimated by clinical assessment.

Sonography is safe, inexpensive, not invasive, and well tolerated. No other imaging modality shares all these features. Our preliminary report supports the view that GSS and PDS may be regarded as useful adjunctive tools for assessing short term soft tissue changes after intra-articular injection treatment with triamcinolone acetonide in the small joints of patients with chronic synovitis. Further studies are obviously needed to better define the role of GSS and PDS in monitoring treatment and to determine their impact on therapeutic decisions.

ACKNOWLEDGEMENTS

Supported by Università degli Studi di Ancona grant No 1104 of 29-03-2001.

Authors’ affiliations

E Filippucci, A Farina, F Salaffi, W Grassi, Department of Rheumatology, Università Politecnica delle Marche, Italy
M Carotti, Department of Radiology, Università Politecnica delle Marche, Italy

Correspondence to: Dr W Grassi, Clinica Reumatologica, Università Politecnica delle Marche, Ospedale A. Murri, Via dei Colli, 52. 60035 Jesi (Ancona), Italy; reuman@unian.it

Accepted 21 July 2003

REFERENCES


